ホーム>>Signaling Pathways>> Proteases>> Endogenous Metabolite>>Nicotinic acid riboside

Nicotinic acid riboside

カタログ番号GC63998

ニコチン酸リボシドは、ヒト細胞のNAD+前駆体です。

Products are for research use only. Not for human use. We do not sell to patients.

Nicotinic acid riboside 化学構造

Cas No.: 17720-18-2

サイズ 価格 在庫数 個数
10 mg
$252.00
在庫あり
50 mg
$675.00
在庫あり
100 mg
$1,080.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Nicotinic acid riboside is a NAD+ precursor in human cells. Nicotinic acid riboside is an authentic intermediate of human NAD+ metabolism[1][2].

Nicotinic acid riboside (HepG2 cells; 0.01 nM~0.1 mM) helps FK866-treated cells to maintain viability at low micromolar concentrations[1]..Nicotinic acid riboside formation and release are caused by overexpression of FLAG-tagged CN-II and CN-III in HEK293 and HepG2 cells. CN-II and CN-III generate Nicotinic acid riboside in vitro by dephosphorylation of nicotinic acid mononucleotide (NAMN)[1].

[1]. Sasaki Y, et al. Nicotinic acid mononucleotide is an allosteric SARM1 inhibitor promoting axonal protection. Exp Neurol. 2021;345:113842.
[2]. Bogan KL, et al. Identification of Isn1 and Sdt1 as glucose- and vitamin-regulated nicotinamide mononucleotide and nicotinic acid mononucleotide [corrected] 5’-nucleotidases responsible for production of nicotinamide riboside and nicotinic acid riboside [published correction appears in J Biol Chem. 2010 Jan 29;285(5):3524]. J Biol Chem. 2009;284(50):34861-34869.

レビュー

Review for Nicotinic acid riboside

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Nicotinic acid riboside

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.